Evidence map›Paper›PMID 40439824›Full record

ArticleActa neurochirurgica2025

Temporal muscle thickness as a feasible sarcopenia marker and outcome predictor after aneurysmal subarachnoid hemorrhage.

E Mohajerani, M Gümüs, T F Dinger, C Rieß, L Rauschenbach, J Rodemerk, C D Ziegenfuß, M Darkwah Oppong, Y Ahmadipour, Y Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neurochirurgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

E MohajeraniDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, 45147, Essen, Germany. Emad.mohajerani@uk-essen.de.
M GümüsDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, 45147, Essen, Germany.
T F DingerDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, 45147, Essen, Germany.
C RießDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, 45147, Essen, Germany.
L RauschenbachDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, 45147, Essen, Germany.
J RodemerkDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, 45147, Essen, Germany.
C D ZiegenfußInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, 45147, Essen, Germany.
M Darkwah OppongDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, 45147, Essen, Germany.
Y AhmadipourDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, 45147, Essen, Germany.
Y LiInstitute of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, 45147, Essen, Germany.
P DammannDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, 45147, Essen, Germany.
U SureDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, 45147, Essen, Germany.
R JabbarliDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, 45147, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeSarcopenia has already been investigated as a prognostic marker for many different cancerous and non-cancerous diseases to prognosticate the clinical course. While being a sarcopenia marker, temporal muscle thickness (TMT) has gained increasing interest in recent years as a potential outcome predictor. The aim of this retrospective study was to investigate the association between TMT and the neurological outcome of patients with aneurysmal subarachnoid hemorrhage (aSAH).

methodsA retrospective database consisting of consecutive aSAH cases treated from 01/2003 to 06/2016 was used. The initial computed tomography examinations were used to calculate the mean TMT values. Our primary endpoint was unfavorable outcome at 6 months defined as modified Rankin Scale > 3. Secondary endpoints included the occurrence of angiographic vasospasm and intracranial hypertension (> 20mmHg) during aSAH, in-hospital mortality and development of cerebral infarcts. Univariable analyses were conducted and multivariable analyses were performed on significant findings.

resultsThe mean TMT value of the final cohort (n = 945) was 7.49mm ± 1.68mm. Of the baseline characteristics, a significant relationship with TMT mean value was found for age (p < 0.0001), sex (p < 0.0001), obesity (p = 0.001), hypothyroidism (p = 0.001), and hyperuricemia (p = 0.026). In the final multivariable analysis, the following study endpoints were independently associated with mTMT: in-hospital mortality (p = 0.035, adjusted odds ratio [aOR] 0.86 per-mm-increase, 95% confidence interval [CI] 0.75-0.99), unfavorable outcome at 6 months (p = 0.018, aOR 0.86, 95% CI 0.76-0.98), intracranial hypertension (p = 0.002, aOR 1.17, 95% CI 1.06-1.29) and the occurrence of angiographic vasospasm (p = 0.011, aOR 0.87, 95% CI 0.78-0.97).

conclusionsIn this study, we found significant correlations between mTMT and the clinical course and outcome of patients with aSAH. Further studies in different patient populations are needed to validate the clinical relevance and prognostic value of TMT for aSAH patients.

Indexed as

SarcopeniaSubarachnoid HemorrhageTemporal MuscleAdultAgedFemaleHospital MortalityHumansIntracranial HypertensionMaleMiddle AgedPrognosisRetrospective StudiesTomography, X-Ray ComputedVasospasm, IntracranialOutcome predictionPrognostic markerSarcopeniaSubarachnoid HemorrhageTemporal Muscle Thickness

Identifiers

PMID40439824
PMCPMC12122570

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.